These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29248795)

  • 1. Increased mutability to fosfomycin resistance in Proteus mirabilis clinical isolates.
    Fonseca MRB; Sato JL; Lima-Noronha MA; Migliorini LB; Fernández-Silva FS; Galhardo RS
    Infect Genet Evol; 2018 Mar; 58():27-33. PubMed ID: 29248795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
    Ellington MJ; Livermore DM; Pitt TL; Hall LM; Woodford N
    J Antimicrob Chemother; 2006 Oct; 58(4):848-52. PubMed ID: 16891630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Salmonella genomic island 1 (SGI1) among Proteus mirabilis clinical isolates in Dijon, France.
    Siebor E; Neuwirth C
    J Antimicrob Chemother; 2013 Aug; 68(8):1750-6. PubMed ID: 23580563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report in Africa of two clinical isolates of Proteus mirabilis carrying Salmonella genomic island (SGI1) variants, SGI1-PmABB and SGI1-W.
    Soliman AM; Ahmed AM; Shimamoto T; El-Domany RA; Nariya H; Shimamoto T
    Infect Genet Evol; 2017 Jul; 51():132-137. PubMed ID: 28359833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular screening of antibiotic-resistant determinants among multidrug-resistant clinical isolates of
    Alabi OS; Mendonça N; Adeleke OE; da Silva GJ
    Afr Health Sci; 2017 Jun; 17(2):356-365. PubMed ID: 29062330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community.
    Potron A; Hocquet D; Triponney P; Plésiat P; Bertrand X; Valot B
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and phenotypic profiles of virulence factors and antimicrobial resistance of Proteus mirabilis isolated from chicken carcasses: potential zoonotic risk.
    Sanches MS; Baptista AAS; de Souza M; Menck-Costa MF; Koga VL; Kobayashi RKT; Rocha SPD
    Braz J Microbiol; 2019 Jul; 50(3):685-694. PubMed ID: 31049879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and molecular characterization of antimicrobial resistance in Proteus mirabilis isolates from dogs.
    Harada K; Niina A; Shimizu T; Mukai Y; Kuwajima K; Miyamoto T; Kataoka Y
    J Med Microbiol; 2014 Nov; 63(Pt 11):1561-1567. PubMed ID: 25187600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteus genomic island 1 (PGI1), a new resistance genomic island from two Proteus mirabilis French clinical isolates.
    Siebor E; Neuwirth C
    J Antimicrob Chemother; 2014 Dec; 69(12):3216-20. PubMed ID: 25114166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation].
    Cernohorská L; Chvílová E
    Klin Mikrobiol Infekc Lek; 2011 Jun; 17(3):81-5. PubMed ID: 21780025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
    Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
    J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Biofilm Forming Capability and Antibiotic Resistance in
    Egbule OS; Konye OP; Iweriebor BC
    Pak J Biol Sci; 2024 Apr; 27(5):268-275. PubMed ID: 38840467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.